
Shares of drugmaker Invivyd IVVD.O rise 2% to $2.55 premarket
Company says it identifies a new antibody, VBY329, designed to prevent respiratory syncytial virus or RSV infections in newborns, infants and children
RSV is a virus that can cause serious lung infections in infants
Lab tests show VBY329 works better than company's current medicines nirsevimab and clesrovimab - IVVD
It also fights RSV strains that no longer respond to nirsevimab, company says
Drug is designed to stay longer in the body, which may give babies longer protection - IVVD
Up to last close, shares have jumped more than fivefold YTD